Immunofuse

At Immunofuse we are focused on A New Immunization Modality against Type I Hypersensitivity, Respiratory Viruses, HIV, H. Pylori, Cancer, Ebola, Eosinphilic Esophagitis, Novel and Reinvigorated Antibody Programs, Cancer that enter through the mucosa. Our main focus is the episomal or genomic expression via gene therapy of Dimeric Immunoglobulin A1 (dIgA1) which, becomes secretory immunoglobulin A1 (SIgA1) as part of traversing the epithelium into the mucus. Our gene therapy can work for all including adults of older age and persons with underlying medical conditions because we bypass the adaptive immune system.